Logo
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • Investor Overview
  • NEWS
Menu Trigger
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • Investor Overview
  • NEWS
  • Corporate Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 17, 2021 8:00am EDT

Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021

Aug 04, 2021 6:30am EDT

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending

Jul 30, 2021 6:30am EDT

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s

Jul 28, 2021 3:07pm EDT

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease

Jul 23, 2021 6:30am EDT

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Jul 12, 2021 6:00am EDT

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 01, 2021 6:30am EDT

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease

Jun 17, 2021 4:30pm EDT

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 14, 2021 5:49pm EDT

Alzamend Neuro Announces Pricing of Initial Public Offering

Mar 12, 2021 6:41am EST

Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Logo
  • Facebook
  • Twitter
  • Alzamend Neuro is a registered mark of Alzamend Neuro Inc.
  • © Copyright 2016 - 2022 | All rights reserved. | Terms of Use